» Articles » PMID: 28303595

Single Intra-articular Injection of Fluvastatin-PLGA Microspheres Reduces Cartilage Degradation in Rabbits with Experimental Osteoarthritis

Overview
Journal J Orthop Res
Publisher Wiley
Specialty Orthopedics
Date 2017 Mar 18
PMID 28303595
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Statins are cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway. The anti-inflammatory effect of statins has been reported in recent years. The present study investigated therapeutic effects of the local administration of statin in osteoarthritis (OA). We assessed clinically used statins and selected fluvastatin for further experimentation, as it showed potent anabolic and anti-catabolic effects on human OA chondrocytes. To achieve controlled intra-articular administration of statin, we developed an intra-articular injectable statin using poly(lactic-co-glycolic acid) (PLGA) as a drug delivery system (DDS). The release profile of the statin was evaluated in vitro. Finally, therapeutic effects of fluvastatin-loaded PLGA microspheres (FLU-PLGA) were tested in a rabbit OA model. Rabbit knees were divided into four subgroups: group 1-A, PLGA-treated group; group 1-B, PLGA contralateral saline control group; group 2-A, FLU-PLGA-treated group; and group 2-B, FLU-PLGA contralateral saline control group. Histological analysis 5 weeks after intra-articular injection revealed that OARSI scores were lower in group 2-A. No significant differences in OARSI scores were observed between groups 1-A, 1-B, and 2-B. This study indicates that a single intra-articular injection of fluvastatin-loaded PLGA microspheres could be a novel therapeutic approach for treating patients with OA. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:2465-2475, 2017.

Citing Articles

Phospholipids and Sphingolipids in Osteoarthritis.

Steinmeyer J Biomolecules. 2025; 15(2).

PMID: 40001553 PMC: 11853253. DOI: 10.3390/biom15020250.


Therapeutic Controlled Release Strategies for Human Osteoarthritis.

Wang D, Liu W, Venkatesan J, Madry H, Cucchiarini M Adv Healthc Mater. 2024; 14(2):e2402737.

PMID: 39506433 PMC: 11730424. DOI: 10.1002/adhm.202402737.


Exploring the causal link among statin drugs and the osteoarthritis risk based on Mendelian randomization research.

Chen W, Sun Z, Xiong X, Tan H, Hu J, Liu C Front Genet. 2024; 15:1390387.

PMID: 39296542 PMC: 11408317. DOI: 10.3389/fgene.2024.1390387.


Association Between Statin Use and the Incidence of Clinically Diagnosed Osteoarthritis: A Nationwide Retrospective Cohort Study in Taiwan.

Lin G, Keller J, Wang L Cartilage. 2024; :19476035241247700.

PMID: 38726681 PMC: 11569678. DOI: 10.1177/19476035241247700.


Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms.

Wei G, Lu K, Umar M, Zhu Z, Lu W, Speakman J Bone Res. 2023; 11(1):63.

PMID: 38052778 PMC: 10698167. DOI: 10.1038/s41413-023-00301-9.